BPC-157 demonstrates exceptional safety in animal toxicology studies, with comprehensive evaluations in mice, rats, rabbits, and dogs failing to establish a lethal dose (LD) across wide dose ranges extending from standard research doses (6 g/kg) to levels exceeding 1000-fold higher concentrations (20 mg/kg), with no evidence of acute toxicity, organ-specific damage, or systemic adverse effects even following repeated high-dose administration
Inflammatory bowel disease represents the most advanced clinical target, with at least one Phase II trial having examined a BPC-157-derivative compound (PL 14736) for ulcerative colitis, showing preliminary evidence of mucosal healing in human patients
99% Purity Independently tested for purity and identity COA Every Batch Searchable Certificates of Analysis online Fast U.S
The TGA reports a number of adverse events and other concerns received for unapproved peptide products, which include: severe allergic reactions, requiring doses of adrenaline and hospitalisation systemic inflammatory response syndrome (SIRS) (severe inflammation in the body), requiring hospital management generalised hypersensitivity symptoms such as fullbody intense itching, palpitations, pain and sweating wide ranging body side effects, including insomnia, blurred vision, extreme tiredness, flulike illness, joint pain and skin sensitivity musculoskeletal injuries, including plantar fasciitis and Achilles tendinitis, and poor product quality, including unsealed packaging from an online supplier
